

Encora acquired at USD 2.35bn EV

Coforge (COFORGE IN) announced the acquisition of US-based Encora at an enterprise value of USD 2.35bn in an all-stock deal. The acquisition likely brings in benefits in terms of COFORGE addressing its gaps in the North American market (especially West and Mid-West regions that contribute only 25% to its North America revenues), expansion of its near shore delivery centers in the LATAM market (which are servicing US clients), scaling up its emerging verticals of Healthcare and Hi-tech. However, valuations at EV/sales of 3.9x appear expensive considering that Encora posted only 7-10% organic revenue growth in the past two years, lower than COFORGE's revenue growth. We downgrade COFORGE to Reduce from Accumulate with a lower TP of INR 1,720 per share.

Deal structure: COFORGE is acquiring Encora at an EV of USD 2.35bn, financed through equity of USD 1.89bn (~INR 170bn) and the balance through bridge loan or QIP to retire high-cost term loan of the Encora group. The company will issue 93.8mn shares on a preferential basis to the sellers at INR 1,815.91 per share (totaling INR 170bn) and accordingly, sellers will hold a 21.25% stake in the combined entity. The sellers include PE firms, Advent International and Warburg Pincus that will continue with the company and are not receiving any cash consideration. The sellers will appoint two board members. Shareholder approval will be secured within 30 days of signing the deal, while regulatory approvals are expected within 4-6 months of the signing. COFORGE likely to replace the current high cost debt of Encora with low cost debt or through a QIP launch in the next 4-6 months.

Rationale for acquisition: i) The US market is set to scale up - Most of COFORGE's US revenue (75%) comes from East and South regions and only 25% is from West and Mid-West regions. This gap is likely to be bridged through this acquisition. COFORGE'S North American region is likely to post 50% revenue growth to USD 1.4bn post the acquisition. ii) Hi-Tech and Healthcare verticals will scale up, likely touching USD 170mn revenue run rate. iii) Nearshore delivery capabilities will expand in the LATAM market with the addition of 3,100+ delivery headcount. iv) Clients within USD 10mn+ revenue bracket will expand by 11 to 45 from 34 currently. v) Revenue per employee and margin profile will improve.

Downgrade to Reduce from Accumulate; TP lowered to INR 1,720: Historically (in FY21-25), COFORGE had reported high teen revenue CAGR on account of stable management, strong order book and specialization in select verticals of BFS, Insurance and Travel. Encora's organic revenue growth, on the other hand, was lower at 7-10%. Despite lower growth, COFORGE is acquiring Encora at 3.9X EV/sales and ~21x EV/EBITDA, in line with COFORGE's multiples, which appears expensive. So, we cut our target multiple for COFORGE from 39x to 34x to reflect higher valuation concern. Organically also, some costs for COFORGE witnessed an uptick in recent quarters, which may strain its margins, going ahead. Thus, we cut our earnings estimates by 7-8% for FY27E and FY28E, respectively. We downgrade COFORGE from Accumulate to Reduce, with TP reduced to INR 1,720 (from INR 2,120). The stock is already down 10% in a week, likely reflecting some above-mentioned concerns. Key upside risk is higher-than-expected growth and earnings.

Key Financials

YE March (INR mn)	FY24	FY25	FY26E	FY27E	FY28E
Revenue (INR mn)	90,089	120,507	161,173	185,644	206,997
YoY (%)	12.4	33.8	33.7	15.2	11.5
EBITDA (INR mn)	15,168	19,982	27,761	32,241	35,495
EBITDA margin (%)	16.8	16.6	17.2	17.4	17.1
Adj PAT (INR mn)	8,341	9,787	14,662	17,133	20,279
YoY (%)	16.3	0.5	77.5	18.9	18.4
Fully DEPS (INR)	25.9	24.4	42.5	50.5	59.7
RoE (%)	24.2	16.2	16.7	17.6	18.8
RoCE (%)	31.8	24.9	23.9	26.0	26.7
P/E (x)	61.6	56.4	38.3	32.7	27.7
EV/EBITDA (x)	38.5	29.3	21.1	18.1	16.5

Note: Pricing as on 26 December 2025; Source: Company, Elara Securities Estimate

29 December 2025

Rating: Reduce Target Price: INR 1,720 Upside: 3%

CMP: INR 1,673

As on 26 December 2025

Key data	
Bloomberg	COFORGE IN
Reuters Code	COFO.NS
Shares outstanding (mn)	335
Market cap (INR bn/USD mn)	560/6,237
EV (INR bn/USD mn)	585/6,507
ADTV 3M (INR mn/USD mn)	3,097/34
52 week high/low	2,005/1,191
Free float (%)	100

Note: as on 26 December 2025; Source: Bloomberg

Price chart



Shareholding (%)	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Promoter	0.0	0.0	0.0	0.0
% Pledge	0.0	0.0	0.0	0.0
FII	42.6	40.2	37.4	34.1
DII	47.9	50.1	52.3	54.9
Others	9.5	9.7	10.3	11.0

Source: BSF

Price performance (%)	3M	6M	12 M
Nifty	5.7	1.6	9.4
Coforge	8.8	(11.9)	(11.5)
NSE Mid-cap	5.3	1.5	6.7
NSE Small-cap	(0.3)	(5.8)	(6.2)

Source: Bloomberg



+91 22 4204 8692

Yash Kudale yash.kudale@elaracapital.com





Financials (YE March)

Tillancials (TE March)					
Income Statement (INR mn)	FY24	FY25	FY26E	FY27E	FY28E
Total Revenue	90,089	120,507	161,173	185,644	206,997
Gross Profit	29,949	39,523	53,696	59,816	65,108
EBITDA	15,168	19,982	27,761	32,241	35,495
EBIT	12,196	15,704	21,209	25,514	29,136
Interest expense	1,256	1,347	1,347	1,347	1,347
Other income	(1,153)	(1,080)	(1,028)	(999)	(495)
Exceptional/ Extra-ordinary items	(261)	(1,666)	(248)	-	-
PBT	10,698	12,961	20,071	24,515	28,641
Tax	2,209	3,326	4,693	5,822	6,802
Minority interest/Associates income	(409)	(1,514)	(964)	(1,560)	(1,560)
Reported PAT	8,080	8,121	14,414	17,133	20,279
Adjusted PAT	8,341	9,787	14,662	17,133	20,279
Balance Sheet (INR mn)	FY24	FY25	FY26E	FY27E	FY28E
Shareholders' Equity	36,266	63,792	70,999	79,565	89,705
Minority Interest	1,003	19,498	21,164	22,724	24,284
Trade Payables	627	1,844	1,844	1,844	1,844
Provisions & Other Current Liabilities	6,899	11,006	11,006	11,006	11,006
Total Borrowings	4,366	1,034	1,034	1,034	1,034
Other long term liabilities	10,949	26,766	36,499	42,198	47,171
Total liabilities & equity	61,077	124,907	143,513	159,338	176,010
Net Fixed Assets	7,629	11,260	10,108	8,981	8,223
Goodwill	11,738	38,430	38,430	38,430	38,430
Intangible assets	4,395	11,296	11,296	11,296	11,296
Business Investments / other NC assets	11,290	16,306	16,306	16,306	16,306
	3,352	8,832	12,928		
Cash, Bank Balances & treasury investments Inventories	3,332	0,032	12,920	24,378	43,587
	18,039	25,771	35,326	40,689	20.600
Sundry Debtors Other Current Assets			·	· · · · · · · · · · · · · · · · · · ·	39,698
Total Assets	4,634	13,012	19,120	19,258	18,470
Cash Flow Statement (INR mn)	61,077 FY24	124,907 FY25	143,513 FY26E	159,338 FY27E	176,010 FY28E
Cashflow from Operations	9,034	12,371	17,579	25,616	34,949
Capital expenditure	(2,655)	(6,144)	(5,400)	(5,600)	(5,600)
Acquisitions / divestitures	57	(20,238)	(3,400)	(3,000)	(3,000)
Other Business cashflow	120	1,899			
Free Cash Flow	6,379	6,227	12,179	20,016	29,349
Cashflow from Financing		16,753			
	(8,870)		(7,207) 4,972	(8,566)	(10,139)
Net Change in Cash / treasury investments	(2,314)	4,641		11,449	19,210
Key assumptions & Ratios	FY24	FY25	FY26E	FY27E	FY28E
Dividend per share (INR)	15.0	15.2	21.2	25.2	29.9
Book value per share (INR)	116.3	191.7	209.1	234.4	264.2
RoCE (Pre-tax) (%)	31.8	24.9	23.9	26.0	26.7
ROIC (Pre-tax) (%)	36.1	27.6	27.2	32.1	38.7
ROE (%)	24.2	16.2	16.7	17.6	18.8
Asset Turnover (x)	12.4	12.8	15.1	19.5	24.1
Net Debt to Equity (x)	0.0	(0.1)	(0.2)	(0.3)	(0.5)
Net Debt to EBITDA (x)	0.1	(0.4)	(0.4)	(0.7)	(1.2)
Interest cover (x) (EBITDA/ int exp)	12.1	14.8	20.6	23.9	26.4
Total Working capital days (WC/rev)	74.1	81.7	85.8	81.0	69.7
Valuation	FY24	FY25	FY26E	FY27E	FY28E
P/E (x)	61.6	56.4	38.3	32.7	27.7
P/Sales (x)	6.2	4.7	3.5	3.0	2.7
EV/ EBITDA (x)	38.5	29.3	21.1	18.1	16.5
EV/ OCF (x)	64.7	47.3	33.3	22.8	16.7
FCF Yield	1.0	1.0	1.9	3.2	4.6
Price to BV (x)	14.4	8.7	8.0	7.1	6.3
Dividend yield (%)	0.9	0.9	1.3	1.5	1.8

Note: Pricing as on 26 December 2025; Source: Company, Elara Securities Estimate



Pro-forma financials and Encore's headline numbers

The combined entity is projected to report USD 2.5bn revenues in FY26. The split of this is as follows: i) AI and product engineering may generate USD 1.5bn, ii) data engineering may post USD 250mn, iii) Cloud USD 500mn and iv) BPO USD 250mn.

Encora's revenue is expected to grow from USD 481mn in FY24 to USD 600mn in FY26, at a CAGR of 11.7% (organic growth of 7-10% in FY24 and FY25). Adjusted EBITDA margin (adjusted for one-time integration and transaction expenses related to prior acquisitions) is 19% for FY25. It was in the range of 17-19% historically while COFORGE is planning to improve margin by a couple of percentage points in the future.

Exhibit 1: FY27 Proforma Financials


Particulars (in US\$Mn)	Coforge	Encora	Combined
Revenue	2,136	690	2,826
EBITDA	384	148	533
EBITDA%	18.0%	21.5%	18.9%
Depreciation	86	9	95
Amortization of Intangibles		39	39
EBIT	298	100	399
EBIT%	14.0%	14.5%	14.1%
Interest Cost	20	0	20
PBT	278	100	379
PBT%	13.0%	14.5%	13.4%
Tax	70	21	91
Minority Interest	5		5
PAT	203	79	283
PAT%	9.5%	11.5%	10.0%
Outstanding Shares (# Mn)**	347.7		468.7
EPS (US\$)	52.1	58.2	53.7

^{*}Workings outlined assumes a year-on-year revenue growth of 15% in FY27 and cost synergies of US\$20Mn.

Note: YoY growth of 15% used for illustration purpose and is not a management guidance; Source: Company, Elara Securities Research




Exhibit 2: Overview of Encora, a Silicon Valley-based AI-led engineering firm



Note: 1 Unaudited numbers as per diligence findings; 2 Derived number based on delivery headcount of ~8,100 as of September 30, 2025; 3 As of November 30, 2025 Source: Company, Elara Securities Research


Exhibit 3: The combined entity is projected to report USD 2.5bn revenues in FY26



Note: Pro forma FY26 market consensus (as per Bloomberg) and not mgmt. guidance; Source: Company, Elara Securities Research



Exhibit 4: COFORGE trading at 32.5x, above its 10-year mean of 25.6x



Note: Pricing as on 26 December 2025; Source: NSE, Company, Elara Securities Estimate

Exhibit 5: Valuation

(INR)	FY27E
Current trailing twelve months (TTM) EPS	35.0
Current Market Price (CMP)	1673.3
Target EPS	50.5
Target EPS period	FY27E
Target Multiple (x)	34
Target price	1,720
Upside (%)	3

Note: Pricing as on 26 December 2025; Source: Elara Securities Estimate


Exhibit 6: Change in estimates

(INR mn)	Earlier estimates		Revised estimates			% change			
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Revenue in USD	1,875	2,134	2,379	1,875	2,134	2,379	-	-	-
Revenue in INR	161,173	185,644	206,997	161,173	185,644	206,997	-	-	-
EBITDA	27,958	33,966	37,909	27,761	32,241	35,495	(0.7)	(5.1)	(6.4)
EBITDA margin (%)	17.3	18.3	18.3	17.2	17.4	17.1	(10) bps	(90) bps	(120) bps
PAT	14,564	18,451	22,144	14,414	17,133	20,279	(1.0)	(7.1)	(8.4)
EPS (INR)	42.9	54.4	65.2	42.5	50.5	59.7	(1.0)	(7.1)	(8.4)
TP (INR)			2,120			1,720			(18.9)
Rating		A	ccumulate			Reduce			

Source: Elara Securities Estimate



Coverage History



Date	Rating	Target Price (INR)	Closing Price (INR)
23-Jun-2023	Buy	5,490	4,499
23-Jun-2023	Buy	6,000	4,819
19-Oct-2023	Buy	6,230	5,109
20-Jan-2024	Buy	8,100	6,278
22-Oct-2024	Accumulate	8,110	7,558
23-Jan-2025	Accumulate	9,950	9,196
05-May-2025	Accumulate	8,870	7,497
04-Jun-2025	Accumulate	1,770	1,499
24-Oct-2025	Accumulate	2,010	1,760
08-Dec-2025	Accumulate	2,120	1,951
26-Dec-2025	Reduce	1,720	1,673

Guide to Research Rating

BUY (B) Absolute Return >+20%

ACCUMULATE (A) Absolute Return +5% to +20%

REDUCE (R) Absolute Return -5% to +5%

SELL (S) Absolute Return < -5%



Disclosures & Confidentiality for non U.S. Investors

The Note is based on our estimates and is being provided to you (herein referred to as the "Recipient") only for information purposes. The sole purpose of this Note is to provide preliminary information on the business activities of the company and the projected financial statements in order to assist the recipient in understanding / evaluating the Proposal. Nothing in this document should be construed as an advice to buy or sell or solicitation to buy or sell the securities of companies referred to in this document. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and should consult its own advisors to determine the merits and risks of such an investment. Nevertheless, Elara Securities (India) Private Limited or any of its affiliates is committed to provide independent and transparent recommendation to its client and would be happy to provide any information in response to specific client queries. Elara Securities (India) Private Limited or any of its affiliates have not independently verified all the information given in this Note and expressly disclaim all liability for any errors and/or omissions, representations or warranties, expressed or implied as contained in this Note. The user assumes the entire risk of any use made of this information. Elara Securities (India) Private Limited or any of its affiliates, their directors and the employees may from time to time, effect or have effected an own account transaction in or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for or solicit investment banking or other business from any company referred to in this Note. Each of these entities functions as a separate, distinct and independent of each other. This Note is strictly confidential and is being furnished to you solely for your information. This Note should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This Note is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Elara Securities (India) Private Limited or any of its affiliates to any registration or licensing requirements within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law, and persons in whose possession this document comes, should inform themselves about and observe, any such restrictions. Upon request, the Recipient will promptly return all material received from the company and/or the Advisors without retaining any copies thereof. The Information given in this document is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This Information is subject to change without any prior notice. Elara Securities (India) Private Limited or any of its affiliates reserves the right to make modifications and alterations to this statement as may be required from time to time. However, Elara Securities (India) Private Limited is under no obligation to update or keep the information current. Neither Elara Securities (India) Private Limited nor any of its affiliates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. This Note should not be deemed an indication of the state of affairs of the company nor shall it constitute an indication that there has been no change in the business or state of affairs of the company since the date of publication of this Note. The disclosures of interest statements incorporated in this document are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. Elara Securities (India) Private Limited generally prohibits its analysts, persons reporting to analysts and their family members from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Any clarifications / queries on the proposal as well as any future communication regarding the proposal should be addressed to Elara Securities (India) Private Limited. It is important to note that any dispute with respect to this research report, would not have access to stock exchange investor redressal forum or arbitration mechanism.

Elara Securities (India) Private Limited was incorporated in July 2007 as a subsidiary of Elara Capital (India) Private Limited.

Elara Securities (India) Private Limited is a SEBI registered Stock Broker in the Capital Market and Futures & Options Segments of National Stock Exchange of India Limited [NSE] and BSE Limited [BSE] and a Depository Participant registered with Central Depository Services (India) Limited [CDSL].

Elara Securities (India) Private Limited's business, amongst other things, is to undertake all associated activities relating to its broking business.

The activities of Elara Securities (India) Private Limited were neither suspended nor has it defaulted with any stock exchange authority with whom it is registered in last five years. However, during the routine course of inspection and based on observations, the exchanges have issued advise letters or levied minor penalties on Elara Securities (India) Private Limited for minor operational deviations in certain cases. Elara Securities (India) Private Limited has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has the certificate of registration been cancelled by SEBI at any point of time.

Elara Securities (India) Private Limited offers research services primarily to institutional investors and their employees, directors, fund managers, advisors who are registered or proposed to be registered.

Details of Associates of Elara Securities (India) Private Limited are available on group company website www.elaracapital.com

Elara Securities (India) Private Limited is maintaining arms-length relationship with its associate entities.

Research Analyst or his/her relative(s) may have financial interest in the subject company. Elara Securities (India) Private Limited does not have any financial interest in the subject company, whereas its associate entities may have financial interest. Research Analyst or his/her relative does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Elara Securities (India) Private Limited does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Associate entities of Elara Securities (India) Private Limited may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Research Analyst or his/her relative or Elara Securities (India) Private Limited or its associate entities does not have any other material conflict of interest at the time of publication of the Research Report.

Artificial Intelligence (AI) tools may have been used only for compilation or collating publicly available research data or internally generated research data during the information gathering and/or summarizing the final report.

Research Analyst or his/her relative(s) has not served as an officer, director or employee of the subject company.

Research analyst or Elara Securities (India) Private Limited have not received any compensation from the subject company in the past twelve months. Associate entities of Elara Securities (India) Private Limited may have received compensation from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities have not managed or co-managed public offering of securities for the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company or third party in connection with the Research Report in the past twelve months.

Disclaimer & Standard warning

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Disclaimer for non U.S. Investors

The information contained in this note is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation.

Coforge



Disclosures for U.S. Investors

Rule 15a6 Disclosure: This research report ("Report") was prepared, approved, published, and distributed by Elara Securities (India) Private Limited a company located outside of the United States (the "Foreign Counterparty"). Avior Capital Markets US LLC ("Avior US"), a US registered broker-dealer, distributes this Report in the US on behalf of the Foreign Counterparty. Only major U.S. institutional investors (as defined in Rule 15a-6 under the US Securities Exchange Act of 1934 (the "Exchange Act") may receive this Report under the exemption in Rule 15a-6. A US institutional investor must effect any transaction in the securities described in this Report through Avior US.

Neither the Report nor any analyst who prepared or approved the Report is subject to US legal requirements or the Financial Industry Regulatory Authority, Inc. ("FINRA") or other US regulatory requirements concerning research reports or research analysts. The Foreign Counterparty is not a registered broker-dealer under the Exchange Act nor is it a member of the Financial Industry Regulatory Authority, Inc., or any other US self-regulatory organisation.

Disclosures on Subject Companies: Analysts of the Foreign Counterparty produced this material solely for informational purposes and the use of the intended recipient. No person may reproduce, this Report under any circumstances. No person may copy or make this Report available to any other person other than the intended recipient.

Avior US distributes this Report in the United States of America. The Foreign Counterparty distributes this Report elsewhere in the world. This document is not an offer, or invitation by or on behalf of Avior US, the Foreign Counterparty, their affiliates, or any other person, to buy or sell any security.

Avior US and the Foreign Counterparty and their affiliates obtained the information contained herein from published information and other sources, which Avior US and the Foreign Counterparty and their affiliates reasonably consider to be reliable.

Avior US and the Foreign Counterparty accept no liability or responsibility whatsoever for the accuracy or completeness of any such information. All estimates, expressions of opinion and other subjective judgments contained herein are valid as of the date of this document. Avior US assumes responsibility for the Report content with regards to research distributed in the US.

Neither Avior US nor the Foreign Counterparty has managed or co-managed a public offering of securities for the subject company in the past 12 months, have not received compensation for investment banking services from the subject company in the past 12 months and do not expect to receive and does not intend to seek compensation for investment banking services from the subject company in the next three months. Avior US and the Foreign Counterparty have not owned any class of equity securities of the subject company. There are no other actual, material conflicts of interest of Avior US and the Foreign Counterparty at the time of the publication of this Report. As of the publication of this Report, Avior US nor the Foreign Counterparty makes a market in the subject securities.

Avior US and its affiliates, to the fullest extent permissible by law, accept no liability of any nature whatsoever for any claims, damages or losses arising from, or in connection with, the contents of this Report or the use, reliance, publication, distribution, dissemination, disclosure, alteration or reproduction of this Report, or any views or recommendations recorded therein.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (i) exchange rates can be volatile and are subject to large fluctuations; (ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Subject to the applicable laws, all transactions should be executed through Avior US. Aside from within this Report, important conflict disclosures can also be found at https://aviorcapital.us/us-regulatory-disclosures/and Investors are strongly encouraged to review this information before investing.

Additional Disclaimer for UK Investors

Note that Elara Securities (India) Private Limited ("Foreign Counterparty") has concluded a MiFID II research intermediary agreement with Avior Capital Markets International Limited ("Avior UK"), regulated by the Financial Conduct Authority (FRN: 191074), pursuant to which Avior UK distributes the Foreign Counterparty's research in the UK, in return for which the Foreign Counterparty pays Avior UK a percentage of the income received in relation to such research. This research report including any recommendations recorded therein ("Report") have been prepared by the Foreign Counterparty, and not by Avior UK.

The Report: (a) has been objectively prepared from public sources which are believed to be reliable and therefore constitutes independent investment research and is presented as such; and (b) may only be distributed to, and relied on by, qualifying investors, who are permitted to receive same in the UK.

Securities, money market instruments, strategies, financial or investment instruments mentioned in this Report may not be suitable for all investors. The information and opinions provided in this Report do not constitute a personal recommendation/investment advice and take no account of the investor's individual circumstances. Investors should consider this Report as only a single factor in making any investment decisions and, if appropriate, should seek advice from an investment advisor. This Report is not an offer, or invitation by or on behalf of Avior UK, the Foreign Counterparty, their affiliates, or any other person, to buy or sell any security.

Save as disclosed otherwise, the Foreign Counterparty's relationship with Avior UK is not reasonably expected to impair the objective presentation of the recommendations in the Report, including any interests or conflicts of interest concerning any financial instruments or the issuers to which the recommendations, directly or indirectly, relate. The Report is deemed to be first disseminated at the date and time recorded on the relevant distribution platform, data network or email (as applicable), and which information is available on request. A list of the Foreign Counterparty's research reports disseminated in the UK over the past 12 months is also available on request.

Avior UK does not assume any responsibility or liability of any nature whatsoever arising from or in connection with the content, use, reliance or dissemination of the Report or any recommendation in respect thereof and disclaims any such liability.

Certification by Each of the Authors of this Report

The analyst(s) (singular includes plural) ("Analyst") certifies that the views expressed in this Report are an accurate representation of the Analyst's personal opinions on the stock or sector as covered and reported on by the Analyst hereinabove. The Analyst furthermore certifies that no part of the Analyst's compensation was, is, or will be related, directly or indirectly, to the specific recommendations or views as expressed in this document. The Analyst is principally responsible for the preparation of this Report and does not have any material conflict of interest at the time of publication of this Report. The Analyst(s) has not served as an officer, director or employee of the subject company in the last 12-month period ending on the last day of the month immediately preceding the date of publication of the Report.

Analyst Certification: In connection with the companies or securities that; each analyst identified in this Report certifies that: The views expressed on the subject companies and securities in this Report reflect their personal views. No part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this Report.

Note that:

- (i) The Foreign Counterparty is the employer of the research analyst(s) responsible for the content of this Report, and
- (ii) Research analysts preparing this Report are resident outside the United States and are not associated persons of any US regulated broker-dealer. Therefore, the analyst(s) are not subject to supervision by a US broker-dealer and are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with US rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

Avior Capital Markets US, LLC is a FINRA registered broker-dealer (CRD # 172595) formed for that purpose in the State of Delaware with its principal office at 45 Rockefeller Plaza, Suite 2335. New York. New York 10111.

Avior Capital Markets International Limited is regulated by the Financial Conduct Authority (FRN: 191074), with its principal office at 10 South Street, Elgin, Scotland IV30 1LE. Elara Securities (India) Private Limited is a SEBI-registered Research Analyst (Regn. No.: INH000000933), Stock Broker (Regn. No.: INZ000238236) and Depository Participant (Regn. No.: IN-DP-370-2018). Its registered address is One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India



India

Elara Securities (India) Private Limited

One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India Tel: +91 22 6164 8500

Europe Elara Capital Plc.

6th Floor, The Grove, 248A Marylebone Road, London, NW1 6JZ, United Kingdom Tel: +44 20 7486 9733

USA

Elara Securities Inc.

230 Park Avenue, Suite 2415, New York, NY 10169, USA Tel: +1 212 430 5870 Fax: +1 212 208 2501

Asia / Pacific Elara Capital (Asia) Pte.Ltd.

One Marina Boulevard, Level 20, Singapore 018989 Tel: +65 6978 4047



Managing Director

Harendra Kumar | harendra.kumar@elaracapital.com | +91 22 6164 8571



Head of Research

Dr Bino Pathiparampil | bino.pathiparampil@elaracapital.com | +91 22 6164 8572

Sales Team



India

Hitesh Danak - hitesh.danak@elaracapital.com - +91 22 6164 8543

Ashok Agarwal - ashok.agarwal@elaracapital.com - +91 22 6164 8558

Himani Sanghavi - himani.sanghavi@elaracapital.com - +91 22 6164 8586



India, APAC & Australia

Sudhanshu Rajpal - sudhanshu.rajpal@elaracapital.com - +91 22 6164 8508 Joshua Saldanha - joshua.saldanha@elaracapital.com - +91 22 6164 8541 Shraddha Shrikhande - shraddha.shrikhande@elaracapital.com - +91 22 6164 8567 Suyash Maheshwari - suyash.maheshwari@elaracapital.com - +91 22 4204 8698



India & UK

Prashin Lalvani - prashin.lalvani@elaracapital.com - +91 22 6164 8544



India & US

Karan Rathod - karan.rathod@elaracapital.com - +91 22 6164 8570



Corporate Access, Conference & Events

Anita Nazareth - anita.nazareth@elaracapital.com - +91 22 6164 8520 Tina D'souza - tina.dsouza@elaracapital.com - +91 22 6164 8595

By clicking this link, you acknowledge and agree to the <u>Terms and Conditions of Research Services</u>

Access our reports on Bloomberg: Type RESP ESEC <GO>

Also available on **Thomson** & **Reuters**

Elara Securities (India) Private Limited

Registered Office Address: One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India Tel: +91 22 6164 8500 CIN: U74992MH2007PTC172297 | SEBI Research Analyst Registration No.: INH000000933

Member of BSE Limited and National Stock Exchange of India Limited | SEBI REGN. NO.: INZ000238236

Member of Central Depository Services (India) Limited | SEBI REGN. NO.: IN-DP-370-2018

Investor Grievance Email ID: investor.grievances@elaracapital.com - Tel. +91 22 6164 8509

Compliance Officer: Mr. Anand Rao - Email ID: anand.rao@elaracapital.com - Tel. +91 22 6164 8509